Pharming Group to Post FY2026 Earnings of $1.24 Per Share, HC Wainwright Forecasts (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) – Investment analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Pharming Group in a report issued on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $1.24 per share for the year, down from their prior estimate of $1.35. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Pharming Group Price Performance

Shares of PHAR opened at $8.68 on Thursday. The stock’s 50 day moving average is $7.90 and its two-hundred day moving average is $8.64. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.20. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $584.55 million, a PE ratio of -54.25 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same period in the prior year, the firm posted $0.02 EPS.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.